Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala

Alphonse Okwera; J. L. Johnson; H. Luzze; P. Nsubuga; H. Kayanja; D. L. Cohn; P. Nunn; J. J. Ellner; C. C. Whalen; R. D. Mugerwa

Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala

Alphonse Okwera, J. L. Johnson, H. Luzze, P. Nsubuga, H. Kayanja, D. L. Cohn, P. Nunn, J. J. Ellner, C. C. Whalen, R. D. Mugerwa

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The human immunodeficiency virus (HIV) is a key factor responsible for the high rates of tuberculosis (TB) in sub-Saharan Africa. Treatment of TB with rifampicin (R, RMP) containing short-course regimens is highly effective in HIV-infected adults. We conducted a study to compare the efficacy and safety of intermittent ethambutol (E, EMB) with two RMP-containing regimens to treat pulmonary TB in HIV-infected patients. SETTING: National Tuberculosis Treatment Centre, Mulago Hospital, Kampala, Uganda. DESIGN: This was a prospective cohort compared to two non-randomised control groups. The study group and the two control arms were treated with 2 months of isoniazid (H), RMP, pyrazinamide (Z) and EMB followed by 6 E₃H₃ for the study group and 4HR or 6HR for controls. RESULTS: Between April 1993 and March 2000, 136 patients were enrolled in the 2EHRZ/E3H3 arm, 147 in the 2EHRZ/4HR arm and 266 in the 2EHRZ/6HR arm. The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. CONCLUSION: The 2EHRZ/6E₃H₃ regimen is safe and effective but has a significant risk of relapse.

Original language	English (US)
Pages (from-to)	39-44
Number of pages	6
Journal	International Journal of Tuberculosis and Lung Disease
Volume	10
Issue number	1
State	Published - Jan 2006
Externally published	Yes

Keywords

Ethambutol
HIV/AIDS
Rifampicin
Treatment
Tuberculosis

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Cite this

Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. / Okwera, Alphonse; Johnson, J. L.; Luzze, H.; Nsubuga, P.; Kayanja, H.; Cohn, D. L.; Nunn, P.; Ellner, J. J.; Whalen, C. C.; Mugerwa, R. D.

In: International Journal of Tuberculosis and Lung Disease, Vol. 10, No. 1, 01.2006, p. 39-44.

Research output: Contribution to journal › Article › peer-review

@article{cd7bbb5854b34c45a0968cad523bddc7,

title = "Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala",

abstract = "BACKGROUND: The human immunodeficiency virus (HIV) is a key factor responsible for the high rates of tuberculosis (TB) in sub-Saharan Africa. Treatment of TB with rifampicin (R, RMP) containing short-course regimens is highly effective in HIV-infected adults. We conducted a study to compare the efficacy and safety of intermittent ethambutol (E, EMB) with two RMP-containing regimens to treat pulmonary TB in HIV-infected patients. SETTING: National Tuberculosis Treatment Centre, Mulago Hospital, Kampala, Uganda. DESIGN: This was a prospective cohort compared to two non-randomised control groups. The study group and the two control arms were treated with 2 months of isoniazid (H), RMP, pyrazinamide (Z) and EMB followed by 6 E3H3 for the study group and 4HR or 6HR for controls. RESULTS: Between April 1993 and March 2000, 136 patients were enrolled in the 2EHRZ/E3H3 arm, 147 in the 2EHRZ/4HR arm and 266 in the 2EHRZ/6HR arm. The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. CONCLUSION: The 2EHRZ/6E3H3 regimen is safe and effective but has a significant risk of relapse.",

keywords = "Ethambutol, HIV/AIDS, Rifampicin, Treatment, Tuberculosis",

author = "Alphonse Okwera and Johnson, {J. L.} and H. Luzze and P. Nsubuga and H. Kayanja and Cohn, {D. L.} and P. Nunn and Ellner, {J. J.} and Whalen, {C. C.} and Mugerwa, {R. D.}",

year = "2006",

month = jan,

language = "English (US)",

volume = "10",

pages = "39--44",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union against Tubercul. and Lung Dis.",

number = "1",

}

TY - JOUR

T1 - Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala

AU - Okwera, Alphonse

AU - Johnson, J. L.

AU - Luzze, H.

AU - Nsubuga, P.

AU - Kayanja, H.

AU - Cohn, D. L.

AU - Nunn, P.

AU - Ellner, J. J.

AU - Whalen, C. C.

AU - Mugerwa, R. D.

PY - 2006/1

Y1 - 2006/1

N2 - BACKGROUND: The human immunodeficiency virus (HIV) is a key factor responsible for the high rates of tuberculosis (TB) in sub-Saharan Africa. Treatment of TB with rifampicin (R, RMP) containing short-course regimens is highly effective in HIV-infected adults. We conducted a study to compare the efficacy and safety of intermittent ethambutol (E, EMB) with two RMP-containing regimens to treat pulmonary TB in HIV-infected patients. SETTING: National Tuberculosis Treatment Centre, Mulago Hospital, Kampala, Uganda. DESIGN: This was a prospective cohort compared to two non-randomised control groups. The study group and the two control arms were treated with 2 months of isoniazid (H), RMP, pyrazinamide (Z) and EMB followed by 6 E3H3 for the study group and 4HR or 6HR for controls. RESULTS: Between April 1993 and March 2000, 136 patients were enrolled in the 2EHRZ/E3H3 arm, 147 in the 2EHRZ/4HR arm and 266 in the 2EHRZ/6HR arm. The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. CONCLUSION: The 2EHRZ/6E3H3 regimen is safe and effective but has a significant risk of relapse.

AB - BACKGROUND: The human immunodeficiency virus (HIV) is a key factor responsible for the high rates of tuberculosis (TB) in sub-Saharan Africa. Treatment of TB with rifampicin (R, RMP) containing short-course regimens is highly effective in HIV-infected adults. We conducted a study to compare the efficacy and safety of intermittent ethambutol (E, EMB) with two RMP-containing regimens to treat pulmonary TB in HIV-infected patients. SETTING: National Tuberculosis Treatment Centre, Mulago Hospital, Kampala, Uganda. DESIGN: This was a prospective cohort compared to two non-randomised control groups. The study group and the two control arms were treated with 2 months of isoniazid (H), RMP, pyrazinamide (Z) and EMB followed by 6 E3H3 for the study group and 4HR or 6HR for controls. RESULTS: Between April 1993 and March 2000, 136 patients were enrolled in the 2EHRZ/E3H3 arm, 147 in the 2EHRZ/4HR arm and 266 in the 2EHRZ/6HR arm. The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. CONCLUSION: The 2EHRZ/6E3H3 regimen is safe and effective but has a significant risk of relapse.

KW - Ethambutol

KW - HIV/AIDS

KW - Rifampicin

KW - Treatment

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=33144471064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144471064&partnerID=8YFLogxK

M3 - Article

C2 - 16466035

AN - SCOPUS:33144471064

VL - 10

SP - 39

EP - 44

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 1

ER -

Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this